Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma

Liver International

Volumn 30, Issue 2, 2010, Pages 198-207

  Huo, Teh Ia ^a,b   Hsu, Chia Yang ^a,b   Huang, Yi Hsiang ^a,b   Hsia, Cheng Yuan ^a,b   Lin, Han Chieh ^b   Lee, Pui Ching ^a   Loong, Che Chuan ^b   Chiang, Jen Huey ^a,b   Chiou, Yi You ^a,b   Lee, Shou Dong ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cirrhosis; DM; Hepatocellular carcinoma; Renal insufficiency; Survival

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; SODIUM;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOEMBOLIZATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; FEMALE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; RADIOFREQUENCY ABLATION; SCORING SYSTEM; SODIUM BLOOD LEVEL;

AGED; CARCINOMA, HEPATOCELLULAR; DIABETES COMPLICATIONS; FEMALE; HOSPITALS, VETERANS; HUMANS; KIDNEY FAILURE, CHRONIC; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RENAL INSUFFICIENCY; SURVIVAL RATE; TAIWAN;

EID: 77950618358     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02143.x     Document Type: Article

References (40)

1. El-Serag HB, Davila JA, Petersen NJ. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003, 139:817-23.
2. Pocobelli G, Cook LS, Brant R. Hepatocellular carcinoma incidence trends in Canada: analysis by birth cohort and period of diagnosis. Liver Int 2008, 28:1272-9.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-36.
4. Squadrito G, Pollicino T, Cacciola I. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 2006, 106:1326-30.
5. García-Compean D, Jaquez-Quintana JO, Maldonado-Garza H. Hepatogenous diabetes. Current views of an ancient problem. Ann Hepatol 2009, 8:13-20.
6. Hampel H, Bynum GD, Zamora E. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. Am J Gastroenterol 2001, 96:2206-10.
7. Polesel J, Zucchetto A, Montella M. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol 2009, 20:353-7.
8. Ikeda Y, Shimada M, Hasegawa H. Prognosis of hepatocellular carcinoma with diabetes mellitus after hepatic resection. Hepatology 1998, 27:1567-71.
9. Toyoda H, Kumada T, Nakano S. Impact of diabetes mellitus on the prognosis of patients with hepatocellular carcinoma. Cancer 2001, 91:957-63.
10. Huo TI, Lui WY, Huang YH. Diabetes mellitus is a risk factor for hepatic decompensation in patients with hepatocellular carcinoma undergoing resection: a longitudinal study. Am J Gastroenterol 2003, 98:2293-8.
11. Huo TI, Wu JC, Lui WY. Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and nonsurgical treatment. Am J Gastroenterol 2004, 99:1479-87.
12. Bruix J, Sherman M, Llovet JM. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001, 35:421-30.
13. Ferenci P, Lockwood A, Mullen K. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002, 35:716-21.
14. Wiesner R, Edwards E, Freeman R. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003, 124:91-6.
15. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:329-38.
16. Llovet JM, Di Bisceglie AM, Bruix J. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:698-711.
17. Lei HJ, Chau GY, Lui WY. Prognostic value and clinical relevance of the 6th Edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma. J Am Coll Surg 2006, 203:426-35.
18. Mazzaferro V, Regalia E, Doci R. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-9.
19. Huo TI, Huang YH, Lin HC. Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am J Gastroenterol 2006, 101:975-82.
20. Huo TI, Lin HC, Huang YH. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. Cancer 2006, 107:141-8.
21. Huo TI, Huang YH, Wu JC. Percutaneous ablation therapy for hepatocellular carcinoma: current practice and future perspectives. J Chin Med Assoc 2005, 68:155-9.
22. Yanaga K, Matsumata T, Hayashi H. Effect of diabetes mellitus on hepatic resection. Arch Surg 1993, 128:445-8.
23. Shimada M, Matsumata T, Akazawa K. Estimation of risk of major complications after hepatic resection. Am J Surg 1994, 167:399-403.
24. Poon RT, Fan ST, Wong J. Does diabetes mellitus influence the perioperative outcome or long term prognosis after resection of hepatocellular carcinoma? Am J Gastroenterol 2002, 97:1480-8.
25. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009, 29:502-10.
26. Bianchi G, Marchesini G, Zoli M. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994, 20:119-25.
27. Chin S, Ramirez S, Greenbaum LE. Blunting of the immediate-early gene and mitogenic response in hepatectomized type 1 diabetic animals. Am J Physiol 1995, 269:E691-700.
28. Mori K, Ozawa K, Yamamoto Y. Response of hepatic mitochondrial redox state to oral load: redox tolerance test as a new predictor of surgical risk in hepatectomy. Ann Surg 1990, 211:438-46.
29. Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 1992, 263:H321-6.
30. Huo TI, Wu JC, Lee PC. Diabetes mellitus as a risk factor of liver cirrhosis in patients with chronic hepatitis B virus infection. J Clin Gastroenterol 2000, 30:250-4.
31. Harrison SA, Kadakia S, Lang KA. Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol 2002, 97:2714-24.
32. Huo TI, Wu JC, Lee PC. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver Int 2004, 24:210-5.
33. Ruf AE, Kremers WK, Chavez LL. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005, 11:336-43.
34. Huo TI, Lee SD, Lin HC. Selecting an optimal prognostic system for liver cirrhosis: the model for end-stage liver disease and beyond. Liver Int 2008, 28:606-13.
35. Kim WR, Biggins SW, Kremers WK. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008, 359:1018-26.
36. Pasternack A, Tenhunen R. Low serum bilirubin in chronic renal failure. Relation to haem metabolism. Clin Chim Acta 1976, 67:85-92.
37. Huo TI, Wu JC, Lee PC. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998, 28:231-6.
38. Serfaty L, Capeau J. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int 2009, 29((Suppl. 2)):13-25.
39. Huo TI, Lin HC, Hsia CY. The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am J Gastroenterol 2007, 102:1920-30.
40. Limquiaco JL, Wong GL, Wong VW. Evaluation of model for end stage liver disease (MELD)-based systems as prognostic index for hepatocellular carcinoma. J Gastroenterol Hepatol 2009, 24:63-9.